FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4364322305> ?p ?o ?g. }

• W4364322305 endingPage "1668" @default.
• W4364322305 startingPage "1649" @default.
• W4364322305 abstract "Rationale: Resistance to 5-fluorouracil (5-FU) chemotherapy remains the main barrier to effective clinical outcomes for patients with colorectal cancer (CRC). A better understanding of the detailed mechanisms underlying 5-FU resistance is needed to increase survival. Interleukin (IL)-33 is a newly discovered alarmin-like molecule that exerts pro- and anti-tumorigenic effects in various cancers. However, the precise role of IL-33 in CRC progression, as well as in the development of 5-FU resistance, remains unclear. Methods: High-quality RNA-sequencing analyses were performed on matched samples from patients with 5-FU-sensitive and 5-FU-resistant CRC. The clinical and biological significance of IL-33, including its effects on both T cells and tumor cells, as well as its relationship with 5-FU chemotherapeutic activity were examined in ex vivo, in vitro and in vivo models of CRC. The molecular mechanisms underlying these processes were explored. Results: IL-33 expressed by tumor cells was a dominant mediator of antitumoral immunity in 5-FU-sensitive patients with CRC. By binding to its ST2 receptor, IL-33 triggered CD4+ (Th1 and Th2) and CD8+ T cell responses by activating annexin A1 downstream signaling cascades. Mechanistically, IL-33 enhanced the sensitivity of CRC cells to 5-FU only in the presence of T cells, which led to the activation of both tumor cell-intrinsic apoptotic and immune killing-related signals, thereby synergizing with 5-FU to induce apoptosis of CRC cells. Moreover, injured CRC cells released more IL-33 and the T cell chemokines CXCL10 and CXCL13, forming a positive feedback loop to further augment T cell responses. Conclusions: Our results identified a previously unrecognized connection between IL-33 and enhanced sensitivity to 5-FU. IL-33 created an immune-active tumor microenvironment by orchestrating antitumoral T cell responses. Thus, IL-33 is a potential predictive biomarker for 5-FU chemosensitivity and favorable prognosis and has potential as a promising adjuvant immunotherapy to improve the clinical benefits of 5-FU-based therapies in the treatment of CRC." @default.
• W4364322305 created "2023-04-12" @default.
• W4364322305 creator A5004040364 @default.
• W4364322305 creator A5007005277 @default.
• W4364322305 creator A5008414326 @default.
• W4364322305 creator A5009902675 @default.
• W4364322305 creator A5011116669 @default.
• W4364322305 creator A5013849962 @default.
• W4364322305 creator A5021816222 @default.
• W4364322305 creator A5022499603 @default.
• W4364322305 creator A5029720669 @default.
• W4364322305 creator A5034291484 @default.
• W4364322305 creator A5039095607 @default.
• W4364322305 creator A5047365731 @default.
• W4364322305 creator A5050527067 @default.
• W4364322305 creator A5067835123 @default.
• W4364322305 creator A5075754246 @default.
• W4364322305 creator A5080125836 @default.
• W4364322305 creator A5091103434 @default.
• W4364322305 date "2023-01-01" @default.
• W4364322305 modified "2023-10-18" @default.
• W4364322305 title "Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer" @default.
• W4364322305 cites W1876452769 @default.
• W4364322305 cites W1898853267 @default.
• W4364322305 cites W1968955229 @default.
• W4364322305 cites W1983312277 @default.
• W4364322305 cites W1994993231 @default.
• W4364322305 cites W1995389009 @default.
• W4364322305 cites W2001649567 @default.
• W4364322305 cites W2002892444 @default.
• W4364322305 cites W2045994086 @default.
• W4364322305 cites W2081439406 @default.
• W4364322305 cites W2088010225 @default.
• W4364322305 cites W2093396768 @default.
• W4364322305 cites W2099355322 @default.
• W4364322305 cites W2109518572 @default.
• W4364322305 cites W2145149316 @default.
• W4364322305 cites W2157710399 @default.
• W4364322305 cites W2164212079 @default.
• W4364322305 cites W2169692356 @default.
• W4364322305 cites W2397508608 @default.
• W4364322305 cites W2486467429 @default.
• W4364322305 cites W2519107733 @default.
• W4364322305 cites W2593349435 @default.
• W4364322305 cites W2610185078 @default.
• W4364322305 cites W2735710638 @default.
• W4364322305 cites W2783225392 @default.
• W4364322305 cites W2892831073 @default.
• W4364322305 cites W2976708906 @default.
• W4364322305 cites W2990089967 @default.
• W4364322305 cites W3003687455 @default.
• W4364322305 cites W3005438011 @default.
• W4364322305 cites W3006010005 @default.
• W4364322305 cites W3017447724 @default.
• W4364322305 cites W3035350645 @default.
• W4364322305 cites W3094321390 @default.
• W4364322305 cites W3119086885 @default.
• W4364322305 cites W3128646645 @default.
• W4364322305 cites W3207158777 @default.
• W4364322305 cites W4205564996 @default.
• W4364322305 cites W4220817929 @default.
• W4364322305 cites W4225113127 @default.
• W4364322305 cites W4281564308 @default.
• W4364322305 doi "https://doi.org/10.7150/thno.80483" @default.
• W4364322305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37056569" @default.
• W4364322305 hasPublicationYear "2023" @default.
• W4364322305 type Work @default.
• W4364322305 citedByCount "2" @default.
• W4364322305 countsByYear W43643223052023 @default.
• W4364322305 crossrefType "journal-article" @default.
• W4364322305 hasAuthorship W4364322305A5004040364 @default.
• W4364322305 hasAuthorship W4364322305A5007005277 @default.
• W4364322305 hasAuthorship W4364322305A5008414326 @default.
• W4364322305 hasAuthorship W4364322305A5009902675 @default.
• W4364322305 hasAuthorship W4364322305A5011116669 @default.
• W4364322305 hasAuthorship W4364322305A5013849962 @default.
• W4364322305 hasAuthorship W4364322305A5021816222 @default.
• W4364322305 hasAuthorship W4364322305A5022499603 @default.
• W4364322305 hasAuthorship W4364322305A5029720669 @default.
• W4364322305 hasAuthorship W4364322305A5034291484 @default.
• W4364322305 hasAuthorship W4364322305A5039095607 @default.
• W4364322305 hasAuthorship W4364322305A5047365731 @default.
• W4364322305 hasAuthorship W4364322305A5050527067 @default.
• W4364322305 hasAuthorship W4364322305A5067835123 @default.
• W4364322305 hasAuthorship W4364322305A5075754246 @default.
• W4364322305 hasAuthorship W4364322305A5080125836 @default.
• W4364322305 hasAuthorship W4364322305A5091103434 @default.
• W4364322305 hasBestOaLocation W43643223051 @default.
• W4364322305 hasConcept C121608353 @default.
• W4364322305 hasConcept C126322002 @default.
• W4364322305 hasConcept C13373296 @default.
• W4364322305 hasConcept C167672396 @default.
• W4364322305 hasConcept C203014093 @default.
• W4364322305 hasConcept C2776090121 @default.
• W4364322305 hasConcept C502942594 @default.
• W4364322305 hasConcept C526805850 @default.
• W4364322305 hasConcept C71924100 @default.
• W4364322305 hasConcept C86803240 @default.

• next